Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: A case-match study

Leukemia and Lymphoma

Volumn 51, Issue 8, 2010, Pages 1444-14449

  Offidani, Massimo ^a   Leoni, Pietro ^a   Bringhen, Sara ^b   Corvatta, Laura ^c   Larocca, Alessandra ^b   Gentili, Silvia ^a   Oliva, Stefania ^b   Polloni, Claudia ^a   Galieni, Piero ^c   Catarini, Massimo ^c   Alesiani, Francesco ^c   Mele, Anna ^c   Brunori, Marino ^c   Blasi, Nicola ^c   Ferranti, Mario ^c   Visani, Giuseppe ^c   Boccadoro, Mario ^b   Palumbo, Antonio ^b  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Marche Multiple Myeloma Network (GEMaMM)   (Italy)

Author keywords

Multiple myeloma; pegylated liposomal doxorubicin; thalidomide; very elderly

Indexed keywords

CIPROFLOXACIN; CREATININE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PREDNISONE; THALIDOMIDE; WARFARIN; ZOLEDRONIC ACID;

AGED; AGED HOSPITAL PATIENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM PREVENTION; HUMAN; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR REGRESSION; VERY ELDERLY;

EID: 77955461166     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.486878     Document Type: Article

References (22)

1. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-2536.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-12120
3. Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993-1999.
4. Ries LA, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review. 1975-2005. Available from: www. seer.cancer.gov
5. Facon T, Mary JY, Pégourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006;107:1292-1298.
6. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664-3670.
7. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-831.
8. Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006;108:2159-2164.
9. Durie BG, Harousseau JL, San Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
10. Phekoo KJ, Schey SA, Richards MA, et al. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004;127:299-304.
11. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomde versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma. Lancet 2007;370: 1209-1218.
12. Gulbrandsen N, Waage A, Gimsing P, et al. A randomised placebo controlled study with melphalan/prednisone vs melphalan/prednisone/thalidomide: quality of life and toxicity. Haematologica 2008;93(Suppl. 1):Abstract 209.
13. Wijermans P, Schaafsma M, Van Norden Y, et al. Melphalan+prednisone vs melphalan+prednisone+ thalidomide in induction therapy for multiple myeloma in elderly patients: first interim results of the Dutch cooperative GROUP HOVON. Haematologica 2008;93(Suppl. 1): Abstract 440.
14. Hernandez JM, Garcia-Sanz R, Golvano E, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004;127: 159-164.
15. Ludwig H, Hajek R, TóthováE, et al. Thalidomidedexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009;113: 3435-3442.
16. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-436.
17. Rajkumar SV, Rosiñol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26:2171-2177.
18. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus lowdose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29-37.
19. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002;100:1168-1171.
20. Zangari M, Barlogie B, Anaissie E, et al. Deep venous thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004;126:715-721.
21. Bradley MA, Begum G, Barth NJ, et al. Early mortality following diagnosis of multiple myeloma: analysis of patients entered into the UK Medical Reasearch Council Trials 1980- 2002. Blood 2004;104(Suppl. 1):944a (Abstract 3465).
22. Ishak J, Dimopoulos MA, Weber D, et al. Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone. Blood 2008;112(Suppl. 1): 1271 (Abstract 3708).